SciTech Development
SciTech Development is a clinical-stage biotechnology company dedicated to revolutionizing cancer treatment through innovative drug delivery platforms and targeted therapies. Their mission is to develop cost-effective therapeutics that deliver transformative clinical outcomes with less patient trauma, focusing on advancing their clinical programs to bring effective cancer treatments to patients worldwide.
Industries
Nr. of Employees
small (1-50)
SciTech Development
P.O. Box 36927, Grosse Pointe Farms, MI 48236
Patents
Liposomal nanoparticles and other formulations of fenretinide for use in therapy and drug delivery
US-8709379-B2
View Details
Liposomal nanoparticles and other formulations of fenretinide for use in therapy and drug delivery
US-8709379-B2
View DetailsProducts
Nanoparticle‑formulated fenretinide for intravenous oncology use
A patent‑protected aqueous nanoparticle formulation combining a poorly soluble small molecule with phospholipid bilayers to enable high‑dose IV administration, improved tissue delivery, and an optimized pharmacokinetic profile for oncology indications.
Nanoparticle‑formulated fenretinide for intravenous oncology use
A patent‑protected aqueous nanoparticle formulation combining a poorly soluble small molecule with phospholipid bilayers to enable high‑dose IV administration, improved tissue delivery, and an optimized pharmacokinetic profile for oncology indications.
Services
Design and operational management of Phase 1 accelerated dose‑escalation trials including site activation, safety monitoring, PK/PD assessments, and MTD determination.
Engineering of nanoparticle formulations to improve solubility, bioavailability, and targeted tissue delivery for small‑molecule therapeutics; development of patentable formulations.
Execution of regulatory strategies to obtain IND acceptance and secure designations that support clinical development timelines.
Selection and management of contract manufacturers to produce clinical‑grade nanoparticle formulations under cGMP sterile conditions and to support manufacturing scale‑up.
Design and operational management of Phase 1 accelerated dose‑escalation trials including site activation, safety monitoring, PK/PD assessments, and MTD determination.
Engineering of nanoparticle formulations to improve solubility, bioavailability, and targeted tissue delivery for small‑molecule therapeutics; development of patentable formulations.
Execution of regulatory strategies to obtain IND acceptance and secure designations that support clinical development timelines.
Selection and management of contract manufacturers to produce clinical‑grade nanoparticle formulations under cGMP sterile conditions and to support manufacturing scale‑up.
Expertise Areas
- Nanoparticle drug delivery
- Formulation development for poorly soluble therapeutics
- Early‑phase clinical trial management (Phase 1a/b)
- GMP clinical manufacturing coordination
Key Technologies
- Nanovesicle/nanoparticle formulations
- Phospholipid bilayer encapsulation
- Liposomal encapsulation
- Nanosuspensions
News & Updates
The contract manufacturing agreement will provide the clinical supply of ST-001, SciTech's lead cancer drug candidate, with delivery expected in Q4 2022, followed by clinical trials for lymphoma.
The company received FDA approval for a new IND targeting the treatment of relapsed/refractory small cell lung cancer following its previous approval for T-Cell NHL.
Encouraging early data from the Phase 1a trial in T-cell Non-Hodgkin Lymphoma supports progressing to the next trial stage.
Updates on early data in T-cell lymphoma, FDA approvals, manufacturing expansion, Series A launch, and investor support.
Announcement of FDA approval for a new IND for small cell lung cancer treatment.
Funding round to support ongoing clinical trials for T-cell lymphoma and small cell lung cancer.
The contract manufacturing agreement will provide the clinical supply of ST-001, SciTech's lead cancer drug candidate, with delivery expected in Q4 2022, followed by clinical trials for lymphoma.
The company received FDA approval for a new IND targeting the treatment of relapsed/refractory small cell lung cancer following its previous approval for T-Cell NHL.
Encouraging early data from the Phase 1a trial in T-cell Non-Hodgkin Lymphoma supports progressing to the next trial stage.
Updates on early data in T-cell lymphoma, FDA approvals, manufacturing expansion, Series A launch, and investor support.
Announcement of FDA approval for a new IND for small cell lung cancer treatment.
Funding round to support ongoing clinical trials for T-cell lymphoma and small cell lung cancer.